10 Stocks Grow Firmer Despite Mixed Market Sentiment

The stock market kicked off the first trading day of the week on a lackluster note, with major indices finishing mixed as it struggled to rebound from Friday’s bloodbath.

The Dow Jones was the sole gainer among the main indices, eking out a 0.08-percent gain. In contrast, the S&P 500 and the tech-heavy Nasdaq both fell 0.50 percent and 1.21 percent, respectively.

Meanwhile, ten companies registered strength, albeit posting only modest gains. This article details the reasons behind their performance.

To come up with Monday’s top gainers, we considered only the stocks with $2 billion in market capitalization and $5 million in daily trading volume.

A man in long sleeves looking at stock market data. Photo by Tima Miroshnichenko on Pexels

10. Bristol-Myers Squibb Co (NYSE:BMY)

Bristol-Myers saw its share prices grow by 3.67 percent on Monday to finish at $57.88 apiece as investors cheered news of the company’s submission of a supplemental biologics license to the Food and Drug Administration for its drug treatment Opdivo plus Yervoy.

The drugs are expected to become a potential first-line treatment option for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

The application followed the successful clinical trial that resulted in superior progression-free survival for the Opdivo plus Yervoy combination.

According to BMY, the FDA granted the application Breakthrough Therapy Designation and Priority Review status and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025.

9. Baxter International Inc. (NYSE:BAX)

Baxter International grew its share prices by 3.73 percent on Monday to close at $35.08 apiece as investor sentiment was buoyed by an investment bank’s upgraded rating for the company.

In a report, UBS raised its price target for BAX by 7.7 percent to $35 from $32.5 previously, while maintaining a ‘neutral’ rating for the company.

The rating adjustment followed the company’s release of its 2024 earnings, where it swung to a net loss attributable to shareholders of $512 million in the last quarter versus the $245 million attributable net income registered in the same period a year earlier.

Net sales were little changed, up only 1 percent to $2.753 billion from $2.729 billion in the same comparable period.

In the full year alone, BAX also registered a net loss attributable to shareholders of $649 million, a reversal from the $2.656 billion attributable net income in 2023.